BRIC-NIPGR Short-Term Research Fellowship for Life sciences candidates
25 May 2026

BRIC-NIPGR Short-Term Research Fellowship for Life sciences candidates

Candidates holding a Masters degree (with at least 55% marks) in in Natural Sciences / Agriculture / Life sciences / Plant biology / Botany.
25 May 2026
DBT funded project positions for sciences candidates at PGIMER
MSc with CSIR-USC NET or any other National Examinations conducted by Central Govt. Dept, and Agencies and Institutions
25 May 2026
BRIC-inStem invites applications for post of Project Associate
Masters Degree in Natural Sciences or Bachelors Degree in Engineering or Technology or Medicine or from a recognized University or equivalent
25 May 2026
Analytical & Bioanalytical Chemistry Lead Job at Alembic Pharmaceutical
This role offers a unique opportunity to contribute to discovery programs in India while actively bridging into the U.S. biotech ecosystem, collaborating with global scientific partners to help deliver transformational medicines.
25 May 2026
Quality Control and Quality Assurance Jobs at Concord Biotech
Having Experience in Microbial limit test of Raw material, finished, Stability products and development samples. Microbial testing, Environment monitoring of classified area.
25 May 2026
Interviews for Production, Warehouse, Micro and QA at Natco Pharma
Experience in handling vial / cartridge filling, capping, compounding, washing and depyrogenation and component preparation.
25 May 2026
Work as Formulation Development Head at KMS Health Center
Lead and oversee end-to-end formulation development programs for generic drug products including solid oral dosage forms, liquids, and injectables.
25 May 2026
Sun Pharma Reports Strong FY26 Performance, Announces ₹5 Final Dividend

India’s largest pharmaceutical company, Sun Pharmaceutical Industries has reported robust financial results for the financial year ended March 31, 2026, while also announcing a final dividend of ₹5 per equity share for shareholders.

25 May 2026
Glenmark Pharma’s US Arm Agrees 29.6 Million USD Settlement in Generic Drug Pricing Case

Glenmark Pharmaceuticals announced that its US-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to settle long-running antitrust litigation in the United States related to alleged price-fixing and anti-competitive practices in the generic drug market.

According to the company’s regulatory filing submitted to the stock exchanges, Glenmark USA will pay a total settlement amount of 29.628 million USD in annual instalments over five years. The settlement is still subject to approval by the court overseeing the litigation.

25 May 2026
Gilead’s Hepcludex Becomes First FDA-Approved Therapy for Hepatitis D Infection

In a major breakthrough for liver disease treatment, Gilead Sciences has received accelerated approval from the U.S. FDA for Hepcludex (bulevirtide-gmod), making it the first and only approved therapy for chronic Hepatitis Delta Virus (HDV) infection in the United States.